Navigation Links
Mechanisms involved with tumor relapse identified

Researchers at Virginia Commonwealth University’s Massey Cancer Center studying the interaction between the immune system and cancer cells have identified interferon gamma as one of the signaling proteins involved with tumor relapse.

The findings may help researchers develop tailored vaccines and other immunotherapeutic strategies to fight a number of cancers. Immunotherapy involves the manipulation of the immune system ?by introducing an antibody or lymphocytes, or immunization with a tumor vaccine ?to recognize and eradicate tumor cells.

Using a transgenic mouse model of breast cancer, researchers found that interferon gamma, a cytokine or chemical messenger that is produced by cells of the immune system upon activation, plays a role in tumor relapse. In humans, interferon gamma is also produced by white blood cells of the immune system in response to invasion by pathogens or tumors in order to protect the host against infection or cancers. Production of interferon gamma by lymphocytes against tumors is considered a sign of good prognosis; however, recent study findings indicate that this may not be the case. The findings were reported in the March 2007 issue of the European Journal of Immunology, the official journal of the European Federation of Immunological Societies.

"By understanding the molecular mechanisms involved with tumor relapse, we can create tailored vaccines that can induce specific types of immune responses in patients, rather than inducing a broad range of immune responses - some of which may be detrimental or may induce tumor relapse," said lead investigator, Masoud H. Manjili, D.V.M., Ph.D., a member scientist with the Massey Cancer Center.

"Ultimately, we hope to offer a new polypeptide vaccine approach that induces tumor killing without causing HER-2/neu loss. Loss of HER-2/neu is a mechanism that tumors utilize to escape the immune-mediated destruction," he said.

Since 2000, Manjili and his col leagues have been employing animal models of breast cancer to evaluate anti-tumor efficacy of a vaccine formulation they created. This vaccine formulation combines a heat shock protein 110 (HSP110), as an adjuvant, with a tumor antigen HER-2/neu, as a protein target expressed in breast tumors. Adjuvants are agents that are able to modify another agent ?basically working as a chemical catalyst.
'"/>

Source:Virginia Commonwealth University


Related biology news :

1. UCSD research reveals mechanism involved with type of fatal epilepsy
2. Researchers discover key gene involved in bark beetle pheromone production
3. High-powered gene profiles provide clues to genes involved in common form of lung cancer
4. Molecular steps involved in the creation of gene-silencing microRNAs identified
5. Hunt for human genes involved in cell division under way
6. Genes involved in biofilms
7. Genes involved in cell growth and cell division identified
8. Scientists identify gene involved in stem cell self-renewal in planaria
9. Key molecular signaling switch involved in allergic disease identified
10. Jefferson scientists identify gene mutation potentially involved in breast cancer initiation
11. Pleasure and pain: Study shows brains pleasure chemical is involved in response to pain too

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... June 23, 2016 ReportsnReports.com ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global Cell ...
Breaking Biology Technology: